Kornimate/medical-research-clean huggingface dataset:
improving muslim women's uptake of cancer screening (imcan)

Conditions: Breast Cancer; Bowel Cancer; Cervical Cancer

Summary: the goal of this non-randomised trial is to test how a workshop that includes religiously-tailored messages can help increase the uptake of breast, colorectal and cervical cancer screening among muslim women in north east england and scotland. the results of this trial will inform the development of a full-scale randomised-controlled trial. participants in this study will be asked to take part in a two-hour workshop, deliver either online or in-person.

low rates of cancer screening among muslim women puts them at higher risk of death from screening since they do not detect cancer early. this study will work to increase the uptake of cancer screening among muslim women using two-hour workshops delivered in the community. the workshops were developed with the help of 10 muslim women in scotland. the workshops include four parts: * a discussion on the barriers and facilitators to breast, cervical and colorectal cancer screening * a health information session given by a female health provider on cancer screening * videos of muslim women talking about their experiences with cancer screening * a session given by a female religious scholar to discuss islamic perspectives on cancer screening. another eighteen muslim women then took part in the workshops; they gave positive feedback on the content of the workshops and how the sessions were delivered. in the feasibility trial, the workshops will be delivered to 200 muslim women to find out whether a full-scale randomised-controlled trial can take place. this study will be carried out with the help of 10 muslim women who will give advice on the content of the workshops and plan for implementation; they will also help with the delivery of the workshops. it is expected that this study will lead to changes in knowledge and screening uptake among participants.

Eligibility criteria:
inclusion criteria: * women from any ethnicity identifying as muslim * muslim women aged 25-74 years * muslim women living in north east england or scotland * muslim women who are not up-to-date with all cancer screening they are eligible for; women who are up-to-date with one type of screening but not others would be eligible (for example, women might be up-to-date with breast cancer screening but not cervical or bowel cancer screening) exclusion criteria: * women who do not identify as muslim * women aged less than 25 years or older than 74 years * women who are up-to-date with all the screening they are eligible for * women who had either breast, cervical or bowel cancer before as their knowledge of the disease and treatment would differ from other women who do not have any prior experience with the disease * women who have had breast cancer gene testing and underwent mastectomy and/or hysterectomy

Keywords: cancer screening breast cancer bowel cancer cervical cancer faith-based intervention muslim women
effectiveness of adalimumab (humira®) in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice

Conditions: Moderate to Severe Plaque Psoriasis

Summary: there is clearly a need for further data on the efficacy of biologic agents in the treatment of nail and scalp psoriasis, especially in the routine clinical setting. a few case reports can be found, but no published data exists from non-interventional studies, such as post-marketing observational studies (pmos) that reflect routine clinical practice. the aim of this pmos is to evaluate the long-term (12-month) efficacy of adalimumab in the treatment of nail and scalp psoriatic lesions in routine dermatologic practice.

this is post-marketing observational study (pmos) in which humira® is prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose, population and indication, and following the local prescription and/or reimbursement guidance. follow-up visits are not strictly scheduled, but rather left to the judgment of each investigator within the 12-month study period for each participant. five visits are indicated within the 12-month observational period: baseline and follow-up at 3 months, 6 months, 9 months and at 12 months (study end). as nails are not included in the general measures of disease severity (such as psoriasis area and severity index \[pasi\]), the nail psoriasis severity index (napsi) will be used to assign a score of nail psoriasis. the scalp, though being involved in the general measures of disease severity (e.g. pasi), represents only 4-5% of the body surface and is therefore poorly represented. psoriasis scalp severity index (pssi) will be used to quantify the intensity of scalp psoriasis and its changes during the study. the association between general skin and localized nail and scalp, and changes in quality of life in response to adalimumab therapy will also be examined.

Eligibility criteria:
inclusion criteria: patients will be enrolled in this pmos if they fulfill all of the below criteria: 1. patients with moderate to severe plaque psoriasis eligible for humira therapy according to the local product label and prescription/reimbursement guidelines 2. have significant psoriatic nail affection (total nail psoriasis severity index napsi score of hands and feet ≥ 10) and/or significant psoriatic scalp affection (psoriasis scalp severity index pssi score ≥ 10) 3. adult (≥18 years of age) 4. have negative result of tuberculosis (tb) screening test or tb prophylaxis as per local guidelines 5. willing to provide informed consent if requested by the local law regulations exclusion criteria: patients fulfilling any of the below exclusion criteria will not be eligible for this pmos: 1. meet contraindications as outlined in the latest version of the local summary of product characteristics (smpc) 2. participate in another clinical/observational study

Keywords: post-marketing observational study (pmos) protocol moderate to severe plaque psoriasis treatment of scalp and nail affection effectiveness of adalimumab (humira®)
comparison of mr enteroclysis and mri with per oral contrast using a 6 % mannitol solution.

Conditions: Magnetic Resonance Imaging, Intestine Small, Crohn Disease.

Summary: the purpose of this study is to compare mri enteroclysis with mri of the small bowel with a per oral 6%mannitol solution.our hypothesis is that the peroral technique preform the same way as mri enteroclysis.


Eligibility criteria:
inclusion criteria: * above 18 years * known crohns disease or strong suspicion. * need of a small bowel examination exclusion criteria: * pregnant * electrolyte disturbances. * any mri contraindications.
study of cortisol metabolism in familial partial lipodystrophy type 2

Conditions: Familial Partial Lipodystrophy Type 2

Summary: familial partial lipodystrophic syndromes are characterized by an increase in visceral adipose tissue and an atrophy of subcutaneous adipose tissue. they are associated with a severe metabolic syndrome especially when linked to the mutation of the r482 codon of the lmna gene (familial partial lipodystrophy type 2, fpl2). data in lipodystrophy induced by antiretroviral therapy of hiv suggests an increase in the activity of 11β-hydroxysteroid dehydrogenase type 1 (11bhsd1). this enzyme reactivates cortisone in cortisol in adipose tissues and liver and has associated to obesity and type 2 diabetes mellitus. hence, the hypothesis is that in patients suffering from fpl2 with the r482 codon mutation of the lmna gene, there is an increase in the activity of hsd11b1 which could participate to the metabolic phenotype of the disease.


Eligibility criteria:
inclusion criteria: * familia partial lipodystrophy type 2 (fpl2) with the r482 codon mutation of the lmna gene * social insured * ability to give consent exclusion criteria: * urinary incontinence or inability to collect urine for 24 hours * moderate and severe kidney insufficiency * hepatic insufficiency * history of hypercortisolism or adrenal insufficiency * treatment interfering with the cortisol metabolism: taking oral or inhaled glucocorticoids within the last 6 months * pregnant and lactating woman.

Keywords: cortisol lipodystrophy 3 hydroxysteroid 11-β dehydrogenase 1 (hsd11b1) insulin resistance hypertriglyceridemia
oshadi d & oshadi r combined with salvage chemotherapy for relapsed acute myeloid leukemia or lymphoid leukemia patients

Conditions: Acute Myeloid Leukemia; Lymphoid Leukemia

Summary: the study will be a prospective open-label single-center study in previously treated patients with acute myeloid leukemia (aml) or acute lymphoid leukemia (all). treatment efficacy and safety of the combination of oshadi d (dnase in oshadi carrier) and oshadi r (rnase in oshadi carrier) with salvage chemotherapy will be evaluated. oshadi d and oshadi r were shown to have anti-tumor activity and good safety profile. patients will receive oshadi d and oshadi r oral treatment combined with salvage chemotherapy. patient will be evaluated throughout the study for safety and tolerance to multiple dose regimens of oshadi d and oshadi r. efficacy will be determined by percentage of bone marrow blasts assessment at day 28 post therapy initiation.


Eligibility criteria:
inclusion criteria: * patients is diagnosed as aml or all * relapse defined as the presence of disease after the achievement of complete remission(cr). refractory disease is defined as progression from or no response while treated with a previous line chemotherapy regimen, or progression within 30 days of last bone marrow assessment. * male or female ≥ 18 years of age * minimal performance status (ecog 0, ≤2) * patients must have a measurable disease by bone marrow blast counts of \> 5 % of nucleated cells. * written informed consent * adequate hepatic function (lfts up to x4 the normal limits), renal function calculated creatinine clearance (crcl) for adverse effects of \>30) * ability to swallow the medications. * females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after treatment discontinuation. * females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy. exclusion criteria: * active infectious disease uncontrolled by antibiotics. * partially treated induction patients (i.e. day 14 non responding patients). * inability to receive high dose salvage chemotherapy. * patient with known positive hiv serology at screening. * female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study. * evidence of ongoing cardiac dysrhythmias of nci common toxicity criteria for adverse effects (ctcae ) version 3.0 grade 2. * pre-existing mal absorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption. * mental disorders. * inability to give written informed consent.
liver fat as a dietary target for treating cardiometabolic disorders in prediabetes and type 2 diabetes

Conditions: NAFLD; Diabetes Mellitus, Type 2; PreDiabetes

Summary: the overall aim of this study is to investigate the long-term impact of a customized diet aimed at reducing liver fat specifically and a healthy nordic diet on ectopic fat (liver, pancreatic and visceral) and cardiometabolic risk in individuals with prediabetes and type 2 diabetes (t2d).

randomized controlled studies investigating the impact of replacing dietary carbohydrates with polyunsaturated fat (pufa) on liver fat content and cardiometabolic risk in individuals with prediabetes and t2d are lacking. also, the effects of a healthy nordic diet on liver fat content and glycemic control have not be investigated. this study therefore aims to: * investigate the effects of the diets on liver fat content (primary aim) * investigate the effects of the diets on pancreatic fat, visceral fat, lean tissue, glycemic and lipid control * investigate the effects of the diets on plasma markers of de novo lipogenesis (dnl) and desaturation (i.e. stearoyl-coenzyme desaturase 1, scd-1) as well as on hepatic dnl using mri spectroscopy * investigate gene-diet interactions, especially if common gene variants (e.g. in pnpla3) known to increase liver fat and dyslipidemia, may modify the dietary effects. * perform lipidomic analyses to identify potential mechanistic pathways that may associate with diet-induced changes in liver fat, pancreatic fat, visceral fat, insulin sensitivity, dyslipidemia or dnl our hypothesis is that a customized diet will effectively reduce liver fat through suppression of hepatic dnl and scd-1 activity, and thereby improve atherogenic dyslipidemia, insulin resistance and hyperglycemia in individuals with prediabetes and t2d.

Eligibility criteria:
inclusion criteria: * men and women * 30-75 years * bmi 25-40 * t2d (duration ≤10 years, no insulin treatment) or prediabetes (ada definition 2019) without diagnosed cardiovascular disease (cvd) during the last 2 years (e.g. myocardial infarction, stroke or angina pectoris) exclusion criteria: * bmi \>40 * alcohol intake \>20 g/day * unwillingness to follow a new prescribed diet for 1 year * diet-induced weight loss (≥10%) the preceding 3 months of screening * malignant disease * severe kidney and liver disease * heart failure or other severe cvd * claustrophobia or metal parts in the body (mri)

Keywords: nafld diabetes mellitus, type 2 prediabetes fatty acids diet lipogenesis cardiometabolic risk
research in autism: parent intervention

Conditions: Autistic Disorder

Summary: the purpose of this research project was to systematically compare two widely used types of intervention programs for children with autism within a parent training model. in one condition, randomly assigned children were provided with an intervention that typically results in acquisition of expressive words in a large percentage of children diagnosed as having autism, using a well-documented manualized intervention focused on verbal expressive communication only (pivotal response training, prt). in the other condi¬tion, randomly assigned children received a widely used intervention on the same social communication functions using a well-documented manualized augmentative system of intervention (picture exchange communica¬tion system, pecs) that has been reported to produce verbal and nonverbal communication in large percentages of children diagnosed with autism. children in the two conditions were compared for development of verbal and nonverbal communication, changes in disruptive behavior, changes in symptoms of autism, and general adaptive behavior gains. in addition, parent satisfaction and stress measures were gathered in order to assess the effects of each intervention on family functioning.


Eligibility criteria:
inclusion criteria: * diagnosis of autistic disorder or at risk of autistic disorder * age 2-0 to 3-11 years of age * use of fewer than 10 functional words at intake exclusion criteria: * primary diagnosis of mental retardation * neurologic pathology (e.g., pku, encephalitis, brain trauma) * major sensory impairment

Keywords: communication pivotal response training picture exchange communication system
estimation of the mcid for patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: background: the effect of exercise on knee osteoarthritis (oa) is often evaluated with patient-reported scales. the minimal clinically important difference (mcid) values of these scales are needed to understand the change in patients after treatment and to manage the treatment. it is also one of the most important data in calculating the mcid sample size. aim: in the literature, mcid studies for exercise applied to knee oa are limited especially for those who did not undergo surgery. thus new studies are needed. method: 100 patients who were diagnosed with knee osteoarthritis will be recruited for the study. participants will be included in an exercise program tailored to their needs for 15 sessions. womac, oks, lefs scales will be used also knee range of motion will be assessed in the baseline, after treatments and in the 4th month follow up.


Eligibility criteria:
inclusion criteria: * to be diagnosed with knee oa according to the criteria of the american society of rheumatology (acr) (diagnosis of primary knee oa) * stage 2 or 3 according to kellgren lawrence radiological staging criteria * participants with age between 50 and 70 years old * being able to walk without using an assistive device * having a body mass index of less than 30 kg/m² * pain severity is between 3 and 7 according to the numerical pain rating scale exclusion criteria: * patients who received physical therapy or intra-articular injections in the last 6 months * receiving an indication for surgery * have severe hearing, vision and speech impairment * having serious systemic and cardiovascular diseases that interfere with exercise * having a lower extremity deformity * patients with acute inflammation of the knee

Keywords: knee osteoarthritis mcid exercise rehabilitation
the association between advancing age and mortality at 30 days in patients with bacteremia e. coli beta-lactamase phenotype extended spectrum rc15_0421

Conditions: Beta-lactamase Extended Spectrum, E. Coli, Elderly, Mortality, Risk Factor

Summary: in the us and europe, bacteremia are ranked the 7th leading cause of death from all causes. e. coli is one of the main microorganism involved, responsible for 30% to 45% of bacteremia. in europe, bacteremia e. coli, including blse phenotype, have a strong impact on public health, causing increased mortality, particularly in the elderly, and an increase in the average hospital stay. however, few studies have specifically concerned with the criteria associated with mortality of elderly patients with blse e. coli bacteremia. finally, improving epidemiological knowledge of the elderly patients with bacteremia due to blse e. coli has importance in terms of public health and is a prerequisite to the development of preventive strategies and to improve the short-term prognosis.


Eligibility criteria:
inclusion criteria: * all patients with positive blood culture e. coli blse will be included in the study. bacteremia e. coli blse will be defined as the identification of one or more blood cultures positive for e. coli blse in patients with clinical criteria of systemic inflammatory response, at least two of the following 4 criteria: * temperature\> 38 ° c or \< 36 ° c; * heart rate\> 90 beat / min; * respiratory rate \> 20 c / min or paco2 \< 32 mmhg; * wbc \> 12,000 / microl or \< 4000 / microl or 10% immature forms exclusion criteria: * for each patient included, only the first episode of bacteremia will be included in the study
metabolically healthy obesity increases the risks of masld and hyperuricemia

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolically Healthy Obesity; Hyperuricemia

Summary: although metabolically healthy obesity (mho) is often considered a relatively benign obesity, its association with the risk of metabolic dysfunction-associated steatotic liver disease (masld) and hyperuricemia remains unclear. this study examined the associations between mho and other metabolic-obesity phenotypes with masld and hyperuricemia, and explored the mediating roles of metabolic indicators.this study included 11,712 and 13,846 participants from a health examination cohort at the first affiliated hospital of ningbo university for masld and hyperuricemia analyses, respectively. participants were classified into four metabolic-obesity phenotypes, with mho defined as obesity without metabolic syndrome components. the outcomes were masld and hyperuricemia. cox regression and mediation analyses were conducted to assess associations and mediating effects.


Eligibility criteria:
inclusion criteria: 1. underwent comprehensive health examinations at the physical examination center of the first affiliated hospital of ningbo university between 2017 and 2024; 2. aged 18 years or older at baseline; 3. completed an abdominal ultrasound examination during the health check-up. exclusion criteria: 1. underweight status at baseline, defined as bmi \< 18.5 kg/m² ； 2. missing data on height, weight, or components of the metabolic syndrome ; 3. baseline diagnosis of masld or any other liver diseases 4. baseline diagnosis of hyperuricemia
folfox-haic plus lenvatinib and toripalimab vs. folfox-haic plus lenvatinib for advanced hepatocellular carcinoma: a randomized controlled and double-blind trial

Conditions: Hepatocellular Carcinoma

Summary: our previous study showed that hepatic arterial infusion chemotherapy plus lenvatinib and toripalimab improved the survival of advanced hepatocellular carcinoma. however, leep 002 study showded that lenvatinib plus pd-1 antibody is not superior to lenvatinib alone for advanced hepatocellular carcinoma. thus, wo conduct this study to compare hepatic arterial infusion chemotherapy plus lenvatinib and toripalimab with hepatic arterial infusion chemotherapy plus lenvatinib for advanced hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * the diagnosis of hcc was based on the diagnostic criteria for hcc used by the european association for the study of the liver (easl) * patients must have at least one tumor lesion that can be accurately measured according to easl criteria. * barcelona clinic liver cancer-stage c * eastern cooperative oncology group performance status of 0 to 2 * with no previous treatment * no cirrhosis or cirrhotic status of child-pugh class a only * not amendable to surgical resection ,local ablative therapy and any other cured treatment. * this study did not limit hbv dna load. high hbv-dna load was aollowed, but hepatitis-b patient must receive concurrent antiviral therapy. * the following laboratory parameters: hemoglobin ≥ 8.5 g/dl total bilirubin ≤ 30mmol/l serum albumin ≥ 30 g/l asl and ast ≤ 5 x upper limit of normal serum creatinine ≤ 1.5 x upper limit of normal inr ≤ 1.5 or pt/aptt within normal limits absolute neutrophil count (anc) \>1,500/mm3 • ability to understand the protocol and to agree to and sign a written informed consent document exclusion criteria: * evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy * known history of hiv * history of organ allograft * known or suspected allergy to the investigational agents or any agent given in association with this trial. * cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * evidence of bleeding diathesis. * patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. * known central nervous system tumors including metastatic brain disease

Keywords: hepatocellular carcinoma lenvatinib oxaliplatin, fluorouracil and leucovorin hepatic arterial infusion chemotherapy toripalimab